|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM363311718 |
| 003 |
DE-627 |
| 005 |
20231226093054.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109804
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1210.xml
|
| 035 |
|
|
|a (DE-627)NLM363311718
|
| 035 |
|
|
|a (NLM)37838215
|
| 035 |
|
|
|a (PII)S1521-6616(23)00567-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ding, Zetao
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Beyond the classics
|b The emerging value of anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.11.2023
|
| 500 |
|
|
|a Date Revised 28.11.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPLs), which can lead to thrombosis and pregnancy complications. Within the diverse range of aPLs, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) have gained significance in clinical practice. The detection of aPS/PT has proven valuable in identifying APS patients and stratifying their risk, especially when combined with other aPL tests like lupus anticoagulant (LA) and anti-β2-glycoprotein I (aβ2GPI). Multivariate analyses have confirmed aPS/PT as an independent risk factor for vascular thrombosis and obstetric complications, with its inclusion in the aPL score and the Global Anti-Phospholipid Syndrome Score (GAPSS) aiding in risk evaluation. However, challenges remain in the laboratory testing of aPS/PT, including the need for assay standardization and its lower sensitivity in certain patient populations. Further research is necessary to validate the clinical utility of aPS/PT antibodies in APS diagnosis, risk stratification, and management
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Anti-phosphatidylserine/prothrombin antibody
|
| 650 |
|
4 |
|a Antiphospholipid syndrome
|
| 650 |
|
4 |
|a Obstetric complications
|
| 650 |
|
4 |
|a Risk stratification
|
| 650 |
|
4 |
|a Thrombosis
|
| 650 |
|
7 |
|a Prothrombin
|2 NLM
|
| 650 |
|
7 |
|a 9001-26-7
|2 NLM
|
| 650 |
|
7 |
|a Phosphatidylserines
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Antiphospholipid
|2 NLM
|
| 650 |
|
7 |
|a beta 2-Glycoprotein I
|2 NLM
|
| 700 |
1 |
|
|a Pan, Haoyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Zhixia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Chengde
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Hui
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 256(2023) vom: 15. Nov., Seite 109804
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:256
|g year:2023
|g day:15
|g month:11
|g pages:109804
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109804
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 256
|j 2023
|b 15
|c 11
|h 109804
|